Guías HFSA/HFA/JHFS 2021: indicaciones para los médicos no cardiólogos

Bibliografía:

1. Bozkurt B., Coats A.J., Tsutsui H. y cols., Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure, J. Card. Fail., 2021; doi: 10.1016/j. cardfail.2021.01.022
2. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B.: The natural history of congestive heart failure: the Framingham study, N. Engl. J. Med., 1971; 285: 1441‑1446
3. Yancy C.W., Jessup M., Bozkurt B. y cols., 2013 ACCF/AHA guideline for the management of heart failure, Circulation, 2013; 128: e240‑e327
4. Ponikowski P., Voors A.A., Anker S.D. y cols., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur. Heart J, 2016; 37: 2129‑2200
5. Tsutsui H., Isobe M., Ito H. y cols., JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure – digest version, Circ. J., 2019; 83: 2084‑2184
6. Hunt S.A., Baker D.W., Chin M.H. y cols., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), Circulation, 2001; 104: 2996‑3007
7. York M.K., Gupta D.K., Reynolds C.F. y cols., B type natriuretic peptide levels and mortality in patients with and without heart failure, J. Am. Coll. Cardiol., 2018; 71: 2079‑2088
8. Piepoli M.F., Adamo M., Barison A. y cols., Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology, Eur. J. Prev. Cardiol., 2022; 29: 275‑300
9. He Y., Ling Y., Guo W. y cols., Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta analysis, Front Cardiovasc. Med., 2021; 8: 757 596
10. Birks E.J., Drakos S.G., Patel S.R. y cols., Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE HF [Remission from Stage D Heart Failure]): medium term and primary end point results, Circulation, 2020; 142: 2016‑2028
11. Nielsen J.C., Lin Y.J., de Oliveira Figueiredo M.J. y cols., European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population, J. Arrhythm., 2020; 36: 553‑607
12. Hamatani Y., Iguchi M., Ueno K. y cols., Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure, Heart, 2021; 107: 705‑712
13. He W.F., Jiang L., Chen Y.Y. y cols., The association of baseline N‑terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non‑ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study, BMC Cardiovasc. Disord., 2021; 21: 202